title: Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
abstract: There is no way to predict early the growth response to growth hormone (GH) treatment in short children with intrauterine growth retardation (IUGR) or idiopathic short stature (ISS).
  
  
  OBJECTIVE
  To evaluate the capacity of the procollagen type 1 amino-terminal propeptide (P1NP), a new marker of bone formation, to help in this prediction.
  
  
  METHODS
  Longitudinal study of 30 patients treated at 7.7 (range: 2.2-12.5) years for IUGR (n=16) or ISS (n=14) with GH (0.47 and 0.33 or 0.4mg/kg/week respectively). P1NP and insulin-like growth factor I (IGF I) were measured before and after 3-6 months of GH treatment.
  
  
  RESULTS
  Before treatment, IUGR patients were younger and shorter than ISS patients, but their other characteristics were similar. IGF I Z-score (ZS) and P1NP concentrations were positively correlated in the whole population (Rho=0.48; P=0.01). After 3-6 months of treatment, both concentrations increased in IUGR and ISS (P<0.01). They remained correlated only in ISS (Rho=0.54; P<0.05). P1NP before treatment was negatively correlated (Rho=-0.67, P=0.015) with the growth rate (SD) during the first year of treatment in ISS but not in IUGR; IGF I ZS was not. The changes in P1NP for the whole population over 3-6 months, but not the changes in IGF I ZS, were positively correlated with the growth rate (Rho=0.41, P=0.03).
  
  
  CONCLUSIONS
  Lower basal plasma P1NP concentrations predict better growth response to GH treatment during the first year in ISS children. Greater increases in its concentrations after 3-6 months of GH treatment may also predict a better growth response in both ISS and IUGR.
authors.affiliation: Université Paris-Descartes, 75270 Paris Cedex 06, France.
authors.forename: G
authors.initials: G
authors.lastname: Gascoin-Lachambre
authors.forename: C
authors.initials: C
authors.lastname: Trivin
authors.forename: R
authors.initials: R
authors.lastname: Brauner
authors.forename: J-C
authors.initials: JC
authors.lastname: Souberbielle
mesh_terms: D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D004392:Dwarfism / Q000188:drug therapy*; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood*; D013006:Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D010446:Peptide Fragments; D011347:Procollagen; C047202:procollagen Type I N-terminal peptide; D013006:Growth Hormone